disorder, the authors included in their meta-analysis two of our studies, in which we reported that CBD reduces the anxiety induced by experimental models of acute stress. 2, 3 In their review, Black and colleagues mentioned that we found no significant improvement in anxiety symptoms with the use of CBD compared to placebo (pooled standardised mean difference [SMD] -0·87 [95% CI -2·01 to 0·27]; table 3 and appendix p53).
After a thorough reading of the article, we believe that the authors' conclusions with respect to the efficacy of CBD in social anxiety might have been influenced by inaccuracies in the description or analysis of the evidence available. Based on our raw data and the same primary outcome criteria (change in anxiety symptoms), we found that the pooled effect from our two studies showed a significant benefit of CBD compared to placebo in social anxiety (SMD -1·28 [95% CI -1·93 to -0·63; figure) . Including the doubleblind controlled trial (n=37) that examined the impact of daily CBD for 4 weeks in teenagers with social anxiety disorder, published in Nov, 2019, 4 the outcome of reduced anxiety associated with CBD use compared with placebo remained significant, with even bigger size effect (SMD -1·58 [95% CI -2·08 to -1·07]; I²= 22·4%).
We think that the authors of the review might have either included in their analysis the healthy controls We read with interest the article by Nicola Black and colleagues in The Lancet Psychiatry in which the authors showed that scarce evidence exists to suggest that cannabinoids improve mental disorders and their symptoms, including anxiety. 1 With respect to the effects of cannabidiol (CBD) in patients with social anxiety
